Arpicco S, Dosio F, Brusa P, Crosasso P, Cattel L
Bioconjug Chem. 1997 May-Jun;8(3):327-37. doi: 10.1021/bc970025w.
To improve the in vivo stability of disulfide-linked immunotoxins (ITs), a series of sterically hindered cross-linking reagents were designed and synthesized. These ligands are characterized by a thioimidate group linked to an S-acetyl thiol or a substituted aryldithio group. To select the reagent of choice, several aryldithio thioimidates, substituted with a methyl or a phenyl group adjacent to the disulfide, were analyzed in thiol-disulfide exchange reactions. Also analyzed were the following: (i) the stability and solubility of the linkers in aqueous solution, (ii) the rate of protein derivatization, and (iii) the steric hindrance due to methyl or phenyl group substituents toward cleavage of the disulfide bond by glutathione. Ethyl S-acetyl 3-mercaptobutyrothioimidate (M-AMPT) was chosen as reagent to prepare two types of stable disulfide-containing AR-3-gelonin conjugates (IT2 and IT3). IT2 was prepared by a 3-(4-carboxamidophenyldithio)propionthioimidate (CDPT)-derivatized antibody coupled to the M-AMPT-derivatized gelonin to afford a conjugate characterized by the presence of a methyl group adjacent to the sulfide bond. In the IT3 conjugate, an M-AMPT-derivatized toxin was coupled to the antibody thiolated with M-AMPT and then activated with Ellman's reagent (DNTB). The in vitro and in vivo stabilities of the three immunoconjugates were assayed, respectively, (i) by adding an excess of glutathione and monitoring protein release and (ii) by studying their pharmacokinetic behaviors. The specificity and cytotoxicity of all ITs were analyzed on target and unrelated cell lines, and no significant differences in activity were observed. IT3, consisting of a symmetrical dimethyl-substituted disulfide bond, was substantially more stable in vivo (t1/2 beta = 88.3 h) than the corresponding IT2, characterized by a disulfide-protected monomethyl substituent bond (t1/2 beta = 60.2 h) compared to the unhindered conjugate IT1 (t1/2 beta = 27.9 h). This family of cross-linking reagents therefore offers advantages, such as minimal perturbation of the protein structure and controlled reactivity due to the thioimidate moiety, as well as the capacity to yield immunotoxins possessing substantial stability in vivo.
为提高二硫键连接的免疫毒素(ITs)的体内稳定性,设计并合成了一系列空间位阻交联剂。这些配体的特征在于硫代亚氨酸酯基团与S - 乙酰硫醇或取代的芳基二硫基团相连。为选择合适的试剂,对几种在二硫键相邻位置被甲基或苯基取代的芳基二硫代硫代亚氨酸酯在硫醇 - 二硫键交换反应中进行了分析。还分析了以下内容:(i)连接子在水溶液中的稳定性和溶解性,(ii)蛋白质衍生化速率,以及(iii)甲基或苯基取代基对谷胱甘肽裂解二硫键的空间位阻。乙基S - 乙酰基3 - 巯基丁酰硫代亚氨酸酯(M - AMPT)被选作试剂来制备两种类型的含稳定二硫键的AR - 3 - 相思子毒素缀合物(IT2和IT3)。IT2通过3 - (4 - 羧酰胺苯基二硫代)丙酰硫代亚氨酸酯(CDPT)衍生化的抗体与M - AMPT衍生化的相思子毒素偶联制备,得到的缀合物特征在于硫醚键相邻位置存在甲基。在IT3缀合物中,M - AMPT衍生化的毒素与用M - AMPT硫醇化并随后用埃尔曼试剂(DNTB)活化的抗体偶联。分别通过(i)加入过量谷胱甘肽并监测蛋白质释放以及(ii)研究它们的药代动力学行为来测定三种免疫缀合物的体外和体内稳定性。在靶细胞系和无关细胞系上分析了所有ITs的特异性和细胞毒性,未观察到活性有显著差异。由对称二甲基取代的二硫键组成的IT3在体内(t1/2β = 88.3小时)比相应的以二硫键保护的单甲基取代键为特征的IT2(t1/2β = 60.2小时)稳定得多,与无位阻的缀合物IT1(t1/2β = 27.9小时)相比。因此,这类交联剂具有诸多优势,例如对蛋白质结构的扰动最小,硫代亚氨酸酯部分可控制反应性,以及能够产生在体内具有显著稳定性的免疫毒素。